recent
ebola
viru
outbreak
highlight
therapeut
potenti
antisera
renew
interest
treatment
approach
human
convalesc
sera
may
readili
avail
earli
stage
outbreak
antisera
anim
origin
produc
short
time
frame
compar
adjuv
viruslik
particl
vlp
recombin
modifi
vaccinia
viru
ankara
vesicular
stomat
viru
vsv
express
ebola
viru
antigen
neutral
antibodi
titer
rabbit
immun
adjuv
vlp
similar
immun
replicationcompet
vsv
indic
present
antigen
nativ
conform
rather
de
novo
antigen
express
essenti
product
function
antibodi
approach
also
yield
hightit
antisera
nipah
viru
glycoprotein
illustr
transfer
viru
famili
multiplestep
immunoglobulin
g
purif
use
twostep
ammonium
sulfat
precipit
follow
protein
affin
chromatographi
result
recoveri
function
sustain
vivo
stabil
adjuv
vlpbase
immun
strategi
thu
promis
approach
rapid
gener
therapeut
antisera
emerg
infect
outbreak
emerg
virus
occur
worri
regular
quickli
control
local
other
becom
public
health
event
global
concern
among
pathogen
involv
virus
transmit
directli
caus
sever
diseas
high
mortal
filoviru
henipaviru
consid
world
health
organ
prioriti
pathogen
recent
west
african
ebola
viru
ebov
epidem
result
confirm
case
death
ebov
outbreak
gener
small
rapidli
contain
hold
true
nipah
niv
hendra
hev
virus
far
mainli
caus
local
cluster
infect
small
outbreak
one
current
ongo
india
howev
first
niv
outbreak
malaysia
singapor
result
document
infect
case
fatal
rate
approxim
illustr
challeng
associ
predict
prepar
event
sinc
licens
therapi
vaccin
often
immedi
avail
patient
isol
support
care
contact
trace
main
approach
use
control
outbreak
thu
renew
interest
therapeut
approach
convalesc
sera
hyperimmun
sera
anim
origin
rapidli
avail
passiv
antibodi
treatment
whole
blood
plasma
convalesc
patient
use
experiment
therapi
filoviru
outbreak
sinc
variabl
result
whole
blood
convalesc
donor
given
postexposur
treatment
kikwit
outbreak
seven
eight
patient
surviv
infect
howev
postexposur
treatment
nonhuman
primat
whole
blood
convalesc
donor
replic
success
seen
human
patient
recent
patient
treat
convalesc
plasma
fail
show
signific
improv
surviv
west
african
outbreak
definit
interpret
data
difficult
antibodi
titer
virusneutr
activ
convalesc
plasma
report
postexposur
prophylaxi
studi
ebovinfect
nonhuman
primat
use
hightit
purifi
immunoglobulin
g
igg
convalesc
macaqu
fulli
protect
subsequ
challeng
indic
function
antibodi
titer
may
determin
factor
neutral
antibodi
also
import
mediat
protect
niv
postexposur
passiv
transfer
sera
hamster
immun
either
vaccinia
vesicular
stomat
virus
vsv
express
nivg
protein
provid
protect
lethal
viru
challeng
hamster
model
murin
monoclon
antibodi
bind
either
nivf
nivg
human
monoclon
antibodi
neutral
activ
relat
hendra
viru
g
protein
ferret
gener
passiv
immun
proven
benefici
numer
acut
infect
still
commonli
use
emerg
treatment
lifethreaten
diseas
human
igg
prepar
gold
standard
rabi
tetanu
postexposur
prophylaxi
avail
emerg
treatment
anthrax
pool
human
igg
intraven
use
ivig
use
prophylact
postexposur
treatment
hepat
b
given
patient
complic
measl
infect
risk
sever
diseas
human
convalesc
sera
may
readili
avail
outbreak
situat
antisera
anim
origin
produc
short
time
frame
animalorigin
purifi
igg
igg
fragment
prepar
still
routin
use
antivenom
even
though
immun
hors
inactiv
ebov
fail
yield
effect
therapeut
antisera
equin
hyperimmun
sera
produc
use
ebov
viruslik
particl
vlp
confer
protect
lethal
challeng
rodent
compar
differ
immun
platform
rapid
induct
high
function
antibodi
titer
ebov
niv
optim
subsequ
igg
purif
process
squalenecontain
adjuv
enhanc
ebov
vlpinduc
total
function
antibodi
titer
vlp
effect
platform
display
antigen
nativ
conform
assess
abil
induct
high
function
antibodi
titer
produc
ebov
vlp
cotransfect
human
embyon
cell
plasmid
encod
ebov
zair
strain
mayinga
matrix
protein
fulllength
membraneanchor
glycoprotein
gp
h
supernat
harvest
purifi
concentr
via
ultracentrifug
result
ebov
vlp
prepar
contain
two
major
protein
migrat
coomassiestain
gel
kda
around
kda
fig
western
blot
analysi
identifi
distinct
band
kda
larg
cleavag
fragment
ebovgp
two
band
kda
two
isoform
due
second
upstream
infram
start
codon
fig
evalu
effect
adjuv
total
function
antibodi
respons
group
mice
immun
intramuscularli
ebov
vlp
alon
combin
squalenecontain
waterinoil
sigma
adjuv
oilinwat
titermax
adjuv
alhydrogel
routin
use
anim
immun
boost
week
later
serum
collect
week
immun
kinet
total
neutral
antibodi
respons
follow
first
antibodi
ebovgp
detect
week
approxim
higher
titer
sigma
titermax
adjuv
group
titer
group
gradual
increas
cours
immun
final
titer
induc
nonadjuv
ebov
vlp
similar
alhydrogeladjuv
titermaxadjuv
group
sigma
adjuv
result
higher
final
titer
fig
neutral
antibodi
titer
determin
plaqu
reduct
neutral
test
prnt
recombin
vsv
fig
ebola
vlp
product
antibodi
respons
kinet
b
vlp
prepar
analyz
transfect
cell
harvest
vlpcontain
supernat
purif
concentr
ultracentrifug
sucros
cushion
sampl
separ
sdspage
gel
protein
stain
coomassi
blue
b
transfer
pvdf
membran
blot
stain
polyclon
goat
antiserum
ebov
lane
vlp
sampl
contain
ebola
gp
lane
vlp
sampl
contain
ebola
lane
neg
control
transfect
blot
deriv
experi
process
parallel
c
mice
immun
im
vlp
alon
combin
either
sigma
adjuv
system
titermax
gold
alhydrogel
boost
week
first
immun
final
serum
sampl
collect
week
second
boost
total
antibodi
respons
recombin
ebovgp
c
neutral
antibodi
respons
shown
antibodi
ebovgp
report
reciproc
serum
endpoint
titer
use
ipma
neutral
antibodi
assess
serum
neutral
capac
prnt
symbol
repres
mean
group
n
error
bar
indic
standard
error
mean
yaxi
begin
detect
limit
respect
assay
statist
signific
indic
p
p
express
gp
close
relat
ebov
zair
strain
kikwit
first
neutral
antibodi
detect
second
immun
robust
increas
observ
adjuv
group
increas
titermaxadjuv
alhydrogeladjuv
group
increas
sigma
adjuv
group
fig
lead
us
choos
sigma
adjuv
experi
induct
robust
neutral
antibodi
titer
requir
sever
immun
vlp
lack
abil
de
novo
protein
product
determin
import
aspect
induct
function
antibodi
compar
adjuv
ebov
vlp
vector
vaccin
base
replicationdefici
modifi
vaccinia
ankara
viru
mva
express
either
gp
protein
zair
ebov
strain
alon
combin
unpublish
data
replicationcompet
due
around
amino
acid
sequenc
ident
strong
structur
function
conserv
among
zair
ebovgp
protein
induc
immun
respons
crossreact
within
speci
mice
immun
three
time
interv
total
antibodi
titer
ebovgp
increas
rapidli
initi
immun
group
contrast
adjuv
ebov
vlp
increas
third
immun
mvabas
viral
vector
fig
neutral
antibodi
detect
mvaebovgpimmun
group
first
group
second
immun
slightli
increas
yield
final
titer
around
fig
first
neutral
antibodi
anim
also
detect
first
immun
final
titer
reach
fig
even
though
neutral
antibodi
detect
first
boost
group
immun
adjuv
ebov
vlp
titer
ultim
reach
level
around
fig
illustr
de
novo
protein
express
requir
effici
induct
function
antibodi
immun
adjuv
ebov
vlp
induc
high
neutral
antibodi
titer
rabbit
gener
larger
volum
antisera
optim
purif
process
assess
scalabl
antisera
product
repeat
immun
protocol
rabbit
anim
immun
adjuv
ebov
vlp
mva
ebovgp
boost
week
later
serum
collect
week
second
boost
total
antiebovgp
antibodi
titer
tabl
bottom
row
neutral
antibodi
level
tabl
bottom
row
slightli
higher
titer
seen
mice
valid
immun
scheme
differ
speci
put
titer
obtain
immun
rabbit
clinic
relev
context
total
antiebov
antibodi
quantifi
valid
wholevirion
ebov
antibodi
captur
enzymelink
immunosorb
assay
elisa
use
assess
antibodi
respons
survivor
ebov
viru
diseas
west
african
outbreak
well
viru
neutral
assay
vnt
ebov
zair
strain
mayinga
use
assess
antibodi
respons
vaccin
volunt
use
assay
optic
densiti
od
valu
rabbit
sera
test
valid
wholevirion
ebov
elisa
rang
thu
compar
hightit
convalesc
sera
patient
clear
viru
endpoint
titrat
reveal
compar
total
antibodi
titer
ebov
ebovgp
tabl
neutral
antibodi
titer
assess
vnt
ebov
mvaebovgp
rabbit
sera
vlp
rabbit
sera
higher
averag
geometr
mean
neutral
endpoint
titer
fig
comparison
total
neutral
antibodi
respons
ebovgp
induc
mice
use
differ
immun
approach
anim
immun
im
pfu
ffu
either
mvaebovgp
ebov
vlp
combin
sigma
adjuv
boost
week
later
final
serum
collect
week
second
boost
total
antibodi
respons
recombin
ebovgp
neutral
antibodi
respons
b
shown
antibodi
ebovgp
report
reciproc
serum
endpoint
titer
use
ipma
neutral
antibodi
assess
serum
neutral
capac
prnt
symbol
repres
mean
group
n
error
bar
indic
standard
error
mean
yaxi
begin
detect
limit
respect
assay
statist
signific
indic
p
tabl
comparison
total
antibodi
respons
ebov
ebovgp
induc
rabbit
use
differ
antigen
express
approach
gener
therapeut
antisera
emerg
virali
r
schmidt
et
al
vaccin
day
tabl
indic
titer
rabbit
hyperimmun
sera
within
therapeut
rang
systemat
bridg
studi
would
requir
directli
correl
inhous
offici
diagnost
assay
similar
rel
proport
titer
induc
differ
immun
platform
indic
suitabl
initi
analys
vlpbase
antisera
product
applic
emerg
viral
infect
immun
recombin
virus
vlp
contain
niv
fusion
f
attach
g
surfac
gp
suffici
elicit
protect
immun
respons
consider
crossreact
differ
niv
even
hendra
viru
strain
evalu
applic
vlpbase
immun
approach
product
hightit
antisera
emerg
virus
niv
vlp
gener
cotransfect
cell
plasmid
encod
niv
matrix
protein
combin
either
f
g
protein
niv
malaysia
strain
h
supernat
harvest
purifi
concentr
via
ultracentrifug
result
nivmg
nivmf
vlp
prepar
show
distinct
band
migrat
coomassiestain
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
sdspage
gel
fig
band
correspond
nivm
kda
nivg
kda
two
band
repres
uncleav
nivf
cleav
nivf
approxim
kda
respect
could
readili
detect
western
blot
analysi
fig
assess
total
function
antibodi
respons
induc
immun
respect
niv
gp
two
rabbit
immun
intramuscularli
nivmf
nivmg
vlp
combin
sigma
adjuv
anim
boost
week
later
serum
collect
immun
week
second
boost
follow
kinet
total
neutral
antibodi
respons
antibodi
nivf
rabbit
immun
nivmf
vlp
detect
first
immun
induct
antibodi
nivg
requir
two
immun
nivmg
vlp
fig
subsequ
immun
increas
total
antibodi
titer
titer
nivf
antibodi
ultim
reach
level
approxim
two
time
higher
nivg
antibodi
fig
consist
find
neutral
antibodi
titer
malaysia
strain
found
nivmf
vlp
group
first
immun
neutral
antibodi
nivmg
first
detect
second
immun
titer
increas
group
anim
third
fourth
immun
fig
neutral
titer
nivf
nivg
glycoprotein
approx
well
level
neutral
activ
neutral
unitsml
protect
lethal
niv
challeng
passiv
transfer
studi
suggest
rabbit
antiniv
gp
sera
would
also
provid
similar
degre
protect
multistep
purif
process
yield
igg
f
sampl
high
recoveri
neutral
activ
acut
delay
advers
reaction
antisera
anaphylact
shock
serum
sick
caus
immunogen
xenogen
serum
protein
complement
activ
fc
portion
whole
igg
prepar
respect
minim
risk
unwant
side
effect
establish
multistep
purif
concentr
procedur
use
sera
ebov
vlpimmun
rabbit
first
serum
protein
precipit
twostep
precipit
use
ammonium
sulfat
follow
igg
affin
chromatographi
use
protein
next
igg
modifi
pepsin
digest
remov
fc
portion
gener
f
prepar
fig
accur
compar
antibodi
titer
cours
purif
process
titer
express
rel
volum
sampl
purif
concentr
illustr
coomassiestain
nonreduc
sdspage
gel
load
protein
concentr
initi
serum
purif
intermedi
precipit
igg
f
prepar
fig
ammonium
sulfat
precipit
even
subsequ
igg
affin
purif
neutral
activ
recov
fig
pepsin
digest
led
around
loss
neutral
activ
f
prepar
compar
unmodifi
serum
indic
multistep
purif
process
result
high
yield
purifi
igg
prepar
littl
loss
function
antibodi
titer
f
fragment
least
recoveri
function
activ
compar
vivo
stabil
homolog
xenogen
antibodi
mice
antibodi
halflif
import
efficaci
determin
passiv
immun
therapi
assess
antibodi
stabil
differ
speci
mice
treat
intraperiton
ip
purifi
homolog
mous
igg
heterolog
rabbit
igg
prepar
dose
calcul
base
total
antiebovgp
antibodi
titer
fig
antibodi
level
recipi
mice
remain
stabl
day
inject
regardless
origin
igg
treatment
higher
igg
dose
result
increas
detect
titer
recipi
fig
sinc
f
fragment
reduc
incid
advers
event
due
lack
interact
fc
receptor
increasingli
use
treat
snake
envenom
howev
associ
shorter
halflif
may
greater
impact
context
amplifi
viru
singl
dose
venom
determin
stabil
heterolog
rabbit
f
prepar
inject
mice
intraperiton
differ
dose
contrast
igg
f
fragment
detect
first
day
transfer
even
higher
dose
use
fig
indic
longer
halflif
igg
combin
potenti
side
effect
may
weigh
lower
stabil
reduc
activ
f
fragment
unpreced
magnitud
western
african
ebov
outbreak
result
deploy
novel
vaccin
therapi
alreadi
advanc
stage
clinic
develop
howev
mani
emerg
virus
develop
far
advanc
need
treatment
option
rapidli
produc
clinic
relev
qualiti
quantiti
explor
potenti
gener
animalorigin
hyperimmun
sera
time
tabl
comparison
neutral
antibodi
respons
ebov
induc
rabbit
use
differ
antigen
express
approach
n
mvaebovgp
n
vlp
adjuv
n
endpoint
titer
log
vnt
titer
log
prnt
gener
therapeut
antisera
emerg
virali
r
schmidt
et
al
frame
use
ebov
niv
model
antigen
found
adjuv
vlp
effect
mvabas
vsvbase
express
vector
induc
hightit
function
antibodi
repeat
immun
reach
level
put
protect
threshold
respect
pathogen
optim
purif
protocol
combin
ammonium
sulfat
precipit
follow
protein
affin
purif
yield
concentr
polyclon
igg
maintain
function
activ
vivo
stabil
indic
approach
may
feasibl
emerg
situat
monoclon
antibodi
neutral
ebov
protect
small
anim
model
often
fail
provid
protect
relev
nhp
model
success
zmapp
monoclon
antibodi
cocktail
demonstr
target
one
antigen
site
includ
nonneutr
epitop
improv
efficaci
polyclon
antisera
advantag
inher
target
multipl
neutral
nonneutr
epitop
given
antigen
therebi
reduc
risk
escap
mutant
emerg
anoth
known
limit
monoclon
antibodi
therapi
broader
specif
also
uniqu
asset
earli
stage
outbreak
pathogen
yet
fulli
character
sinc
crossreact
alreadi
avail
antisera
relat
strain
quickli
ascertain
may
provid
immedi
treatment
option
even
though
immun
hors
inactiv
ebov
fail
produc
effect
therapeut
antisera
recent
approach
use
adjuv
recombin
ebovgp
ectodomain
immun
sheep
led
antisera
effect
postexposur
treatment
rodent
product
fulli
human
polyclon
antibodi
immun
transchromosom
cattl
ebovgp
nanoparticl
constitut
import
step
may
limit
avail
purif
character
igg
f
prepar
antiserum
rabbit
immun
three
time
vlpadjuv
combin
collect
week
final
boost
overview
purif
process
show
twostep
precipit
ammonium
sulfat
satur
buffer
exchang
desalt
follow
igg
isol
use
protein
affin
chromatographi
f
prepar
pepsin
digest
intermedi
final
prepar
resuspend
initi
volum
appropri
concentr
b
protein
analysi
purif
intermedi
ten
microgram
total
protein
prepar
separ
nonreduc
sdspage
stain
coomassi
blue
lane
initi
antiserum
lane
resuspend
protein
follow
precipit
lane
elut
protein
affin
chromatographi
lane
igg
pepsin
digest
total
protein
concentr
assess
bca
assay
shown
sdspage
blot
deriv
experi
process
parallel
c
neutral
antibodi
respons
ebovgp
initi
antiserum
n
intermedi
precipit
n
affinitypurifi
igg
n
f
prepar
affinitypurifi
igg
n
assess
serum
neutral
capac
prnt
bar
repres
mean
group
error
bar
indic
standard
error
mean
mice
receiv
singl
dose
either
purifi
homolog
mous
igg
heterolog
rabbit
igg
f
prepar
ip
inject
detect
antibodi
report
reciproc
serum
endpoint
titer
use
ipma
assay
symbol
repres
singl
anim
correspond
line
group
indic
geometr
mean
n
yaxi
begin
detect
limit
respect
assay
gener
therapeut
antisera
emerg
virali
r
schmidt
et
al
express
repeat
exposur
antigen
nativ
conform
requir
induct
high
function
antibodi
titer
strong
neutral
antibodi
respons
seen
immun
adjuv
vlp
ebov
also
niv
demonstr
potenti
approach
extend
emerg
pathogen
determin
vlp
format
viru
famili
flavivirus
coronavirus
orthomyxovirus
known
mediumscal
largescal
transient
transfect
process
increasingli
use
custom
antigen
protein
product
could
conceiv
form
basi
plugandplay
system
antigen
emerg
virus
either
synthes
clone
express
purifi
use
product
process
use
immun
serumproduc
anim
regulatori
requir
regard
qualiti
safeti
antigen
adjuv
use
product
antisera
differ
consider
vaccin
appli
directli
patient
sinc
manufactur
therapeut
antisera
antigenindepend
exist
process
facil
could
use
littl
adapt
produc
pathogenspecif
antisera
emerg
situat
furthermor
pathogen
potenti
high
public
health
impact
licens
food
drug
administr
anim
rule
ema
orphan
medicin
design
subsequ
stockpil
could
envisag
vlp
long
licens
hepat
b
human
papillomaviru
vaccin
among
candid
platform
emerg
infect
gener
therapeut
antisera
vlp
combin
sever
advantag
noninfecti
thu
handl
without
biosafeti
concern
adjuv
boostabl
produc
varieti
cell
line
ebov
combin
nonneutr
antibodi
target
glycan
cap
make
monoclon
antibodi
cocktail
zmapp
potent
indic
nativ
glycosyl
profil
could
one
crucial
factor
induct
effect
polyclon
antibodi
gener
mammalian
express
system
abl
produc
posttransl
modif
ptm
human
cell
line
advantag
produc
complex
protein
fulli
human
ptm
similar
natur
synthet
human
recent
report
demonstr
efficaci
polyclon
antisera
gener
immun
vlp
produc
insect
cell
express
system
howev
differ
nglycosyl
oglycosyl
profil
human
insect
cell
deriv
filoviru
gp
report
may
affect
qualiti
antisera
limit
applic
system
pathogen
multiplestep
purif
observ
similar
vivo
stabil
xenogen
rabbit
igg
homolog
mous
igg
prepar
recipi
mice
rabbit
f
detect
day
transfer
short
halflif
f
prepar
also
observ
earlier
studi
singl
dose
antisera
result
better
protect
longer
period
compar
repeat
treatment
f
fragment
process
stabil
f
prepar
develop
full
igg
known
control
risk
advers
event
may
valuabl
addit
toolbox
newli
emerg
infecti
diseas
vero
cell
atcc
mdck
cell
atcc
cell
atcc
maintain
co
dulbecco
modifi
eagl
medium
dmem
sigmaaldrich
supplement
vv
fetal
bovin
serum
fb
invitrogen
mm
lglutamin
sigmaaldrich
recombin
vesicular
stomat
express
gp
deriv
zair
ebov
isol
kikwit
place
origin
vsv
gp
well
zair
ebov
strain
makona
mayinga
niv
strain
malaysia
grown
vero
cell
viral
titer
zair
ebov
niv
strain
determin
limit
dilut
use
cytopath
effect
cpe
read
concentr
centrifug
h
g
wv
sucros
cushion
resuspend
dmem
phosphatebuff
salin
pb
immun
viral
titer
determin
plaqu
assay
use
avicel
overlay
fmc
corpor
briefli
serial
viru
dilut
dmem
ad
vero
cell
tissu
cultur
plate
overlay
avicel
pb
mix
equal
volum
dmem
fb
incub
h
room
temperatur
gentl
agit
mlwell
avicel
overlay
ad
plate
incub
h
visual
plaqu
mlwell
pb
contain
crystal
violet
paraformaldehyd
pfa
methanol
ad
incub
min
room
temperatur
titer
express
plaqueform
unit
pfu
mva
vector
vaccin
deliv
either
gp
zair
ebov
strain
alon
mvaebovgp
togeth
matrix
protein
produc
viru
amplif
secondari
chicken
embryo
fibroblast
purifi
ultracentrifug
sucros
reconstitut
trisbuff
salin
ph
vaccin
prepar
store
use
qualiti
control
experi
essenti
perform
describ
previous
vaccin
prepar
titrat
plaqu
assay
use
mvaspecif
immunostain
titer
indic
focusform
unit
ffu
construct
mammalian
express
plasmid
encod
matrix
protein
gp
pcaggsebovgp
zair
ebov
strain
mayinga
describ
previous
express
plasmid
encod
matrix
protein
pcgnivm
pcgnivm
myc
gp
fusion
f
pcgnivf
pcgnivf
ha
attach
g
pcgnivg
pcgnivg
flag
niv
strain
malaysia
also
report
product
ebov
vlp
cell
approxim
confluenc
seed
cm
tissu
cultur
flask
cotransfect
plasmid
mix
four
volum
mm
polyethylenimin
reagent
sigmaaldrich
product
niv
vlp
cell
transfect
plasmid
dna
encod
myc
protein
plasmid
dna
encod
either
f
f
ha
g
g
flag
protein
transfect
mixtur
prepar
dmem
without
addit
incub
h
medium
chang
cell
incub
anoth
h
cultur
supernat
harvest
clarifi
centrifug
g
min
vlp
pellet
ultracentrifug
wv
sucros
cushion
h
ebov
vlp
h
niv
vlp
x
g
pellet
resuspend
pb
store
total
antibodi
respons
determin
immunoperoxidas
monolay
assay
ipma
briefli
determin
ebovgpspecif
antibodi
vero
cell
seed
plate
infect
pfu
determin
nivfspecif
nivgspecif
antibodi
respons
mdck
cell
transfect
dna
either
pcgnivf
ha
pcgnivg
flag
plasmid
cell
incub
h
fixat
pfa
serial
dilut
antisera
ad
fix
cell
incub
h
room
temperatur
follow
incub
horseradish
peroxidas
hrp
coupl
secondari
antibodi
visual
stain
sigmaaldrich
total
antibodi
titer
calcul
geometr
mean
reciproc
last
serum
dilut
posit
stain
detect
total
antibodi
respons
whole
ebov
viru
determin
elisa
describ
previous
briefli
particl
zair
ebov
isol
makona
purifi
concentr
ultracentrifug
sucros
cushion
pellet
resuspend
pb
contain
sd
inactiv
boil
min
elisa
plate
coat
inactiv
zair
ebov
isol
makona
rabbit
antisera
ad
respect
dilut
detect
polyclon
hrpcoupl
secondari
antibodi
stain
tmb
gener
therapeut
antisera
emerg
virali
r
schmidt
et
al
kpl
inc
addit
stop
solut
kpl
inc
od
measur
nm
sampl
analyz
duplic
mean
od
valu
correct
subtract
mock
od
valu
valu
obtain
incub
serum
ebov
antigen
endpoint
titrat
serial
serum
dilut
ad
coat
elisa
plate
sampl
analyz
duplic
mean
od
valu
correct
describ
cutoff
calcul
mean
plu
standard
deviat
sd
multipli
mean
sd
neg
rabbit
sera
total
antibodi
titer
express
reciproc
highest
serum
dilut
yield
od
valu
greater
cutoff
od
measur
neutral
antibodi
prnt
assay
viru
neutral
assay
zair
ebov
isol
mayinga
use
prnt
serial
dilut
heatinactiv
antisera
dmem
mix
appropri
volum
pfuml
result
final
concentr
pfuwel
mixtur
incub
room
temperatur
min
ad
confluent
dish
vero
cell
incub
h
room
temperatur
gentl
agit
inoculum
remov
replac
ml
avicel
overlay
plate
incub
h
plaqu
visual
use
crystal
violet
stain
prnt
titer
calcul
averag
reciproc
highest
serum
dilut
reduc
number
plaqu
rel
averag
number
plaqu
posit
control
well
viru
neutral
assay
ebov
perform
describ
previous
briefli
serial
dilut
heatinactiv
rabbit
antisera
prepar
incub
tissu
cultur
infect
dose
tcid
zair
ebov
isol
mayinga
ad
vero
cell
cpe
evalu
day
titer
express
geometr
mean
reciproc
last
serum
dilut
cpe
observ
viru
neutral
assay
niv
antisera
serial
dilut
rabbit
sera
plate
mix
tcid
niv
strain
malaysia
viru
serum
dilut
incub
h
vero
cell
ad
well
cpe
assess
day
neutral
titer
report
geometr
mean
four
replic
experi
infecti
ebov
niv
perform
facil
institut
virolog
philippsunivers
marburg
complianc
german
regul
anim
experi
carri
complianc
regul
german
anim
protect
law
author
darmstadt
germani
balbc
mice
purchas
janvier
sa
new
zealand
white
rabbit
charl
river
germani
gener
mous
antisera
group
balbc
mice
immun
intramuscularli
either
pfu
pfu
either
mvaebovgp
ebov
vlp
mix
ratio
vv
either
sigma
adjuv
system
mg
monophosphoryl
lipid
detoxifi
endotoxin
salmonella
minnesota
mg
synthet
trehalos
dicorynomycol
sigma
titermax
gold
block
polym
squalen
sorbitan
monool
sigma
alhydrogel
invivogen
anim
boost
two
week
first
immun
three
mice
immun
approach
sacrif
day
postimmun
blood
collect
cardiac
punctur
gener
rabbit
ebov
antisera
new
zealand
white
rabbit
immun
intramuscularli
either
pfu
pfu
mvaebovgp
ebov
vlp
mix
ratio
v
v
sigma
adjuv
system
boost
week
later
blood
sampl
collect
margin
ear
vein
day
anim
sacrif
day
postimmun
exsanguin
gener
nivf
nivg
antisera
new
zealand
white
rabbit
immun
intramuscularli
niv
vlp
contain
either
nivmf
nivmg
mix
ratio
vv
sigma
adjuv
system
boost
week
later
blood
sampl
collect
margin
ear
vein
day
anim
sacrif
day
postimmun
exsanguin
test
stabil
respect
antisera
xenogen
transfer
model
balbc
mice
administ
purifi
mous
rabbit
igg
rabbit
f
fragment
intraperiton
inject
three
mice
antiserum
transfer
group
sacrif
day
transfer
blood
collect
exsanguin
rabbit
sera
test
total
antibodi
ebovgp
ipma
igg
purifi
rabbit
antisera
use
multistep
process
first
anim
sera
treat
satur
ammonium
sulfat
pierc
h
remov
serum
protein
less
solubl
igg
precipit
protein
remov
centrifug
g
min
next
ammonium
sulfat
concentr
supernat
adjust
satur
remov
serum
protein
solubl
igg
centrifug
supernat
remov
iggcontain
precipit
dissolv
origin
volum
serum
sampl
use
trishcl
dissolv
precipit
dialyz
trisbuff
salin
kda
molecular
weight
cutoff
mwco
cassett
thermo
scientif
igg
purifi
affin
chromatographi
use
protein
column
vivapur
kit
sartoriu
accord
manufactur
recommend
modif
briefli
ml
precipit
sampl
mix
two
volum
glycinenaoh
nacl
ph
bind
buffer
centrifug
g
min
room
temperatur
let
igg
bind
protein
step
repeat
flow
column
wash
eight
time
bind
buffer
centrifug
g
min
room
temperatur
igg
elut
ml
glycinehcl
elut
buffer
ph
immedi
ml
previous
prepar
trishcl
ph
neutral
buffer
bring
sampl
ph
approxim
concentr
origin
volum
buffer
exchang
igg
sampl
kda
mwco
centrifug
column
vivaspin
sartoriu
use
accord
manufactur
recommend
concentr
igg
dissolv
pb
immun
mm
sodium
acet
buffer
ph
f
prepar
gener
f
fragment
purifi
igg
acet
buffer
mix
pepsin
umg
sigma
ratio
incub
h
digest
stop
addit
tri
base
ph
adjust
final
ph
f
fragment
separ
undigest
igg
separ
kda
mwco
centrifug
concentr
remain
peptid
pepsin
separ
kda
mwco
centrifug
concentr
dissolv
pb
protein
concentr
purifi
vlp
determin
bradford
assay
biorad
bca
assay
thermo
fisher
use
sampl
serum
purif
process
verif
sampl
qualiti
puriti
ebov
vlp
sampl
contain
total
protein
niv
vlp
sampl
contain
total
protein
separ
reduc
sdspage
antiserum
sampl
contain
total
protein
separ
nonreduc
sdspage
stain
coomassi
blue
fisher
bioreag
transfer
polyvinyliden
difluorid
pvdf
membran
millipor
western
blot
analysi
blot
stain
polyclon
goat
antiserum
ebov
viru
work
solut
monoclon
antibodi
flagtag
hatag
cmyctag
sigma
recommend
dilut
detect
respect
epitopetag
niv
protein
statist
analys
perform
use
graphpad
prism
logtransform
data
use
multipl
comparison
analysi
final
mous
sera
oneway
analysi
varianc
tukey
posttest
signific
consid
p
valu
data
report
paper
avail
correspond
author
upon
request
